外阴疼痛治疗市场：依治疗方法、给药途径和最终用户划分－2026-2032年全球市场预测

预计到 2025 年，外阴疼痛治疗市场价值将达到 667.5 亿美元，到 2026 年将成长至 730.4 亿美元，到 2032 年将达到 1,295.1 亿美元，复合年增长率为 9.93%。

主要市场统计数据
基准年 2025	667.5亿美元
预计年份：2026年	730.4亿美元
预测年份 2032	1295.1亿美元
复合年增长率 (%)	9.93%

简要概述外阴疼痛的临床复杂性、医疗保健服务挑战以及对寻求针对性解决方案的相关人员的策略意义。

外阴疼痛是一种复杂且多方面的临床挑战，涉及疼痛管理、妇科护理和慢性病管理等多个领域。患者往往需要经历漫长的诊断过程，症状表现多样，对治疗方法的反应也各不相同。临床医生正在调整诊疗通讯协定，以便根据症状表型和治疗反应更好地对患者进行分层，而研究人员则继续探索其潜在的病理学，涉及神经系统、发炎和肌肉骨骼系统等领域。

变革性的临床、监管和商业性趋势正在重塑外阴炎治疗的治疗范式、证据预期和护理服务模式。

近年来，在临床和商业领域，外阴疼痛的识别、研究和治疗发生了显着变化。诊断框架正朝着多方面评估的方向发展，整合疼痛定位、心理社会评估和骨盆底功能测试，从而为更个人化的治疗方法方案铺平道路。同时，神经调控技术、具有标靶递送机制的局部製剂以及復健方法的进步，也拓展了临床医师可根据患者个别表型製定治疗方案的范围。

美国近期关税政策变化对外阴疼痛治疗用品和服务的供应链、筹资策略和定价谈判的影响。

贸易和关税制度的政策变化可能会对与外阴疼痛治疗相关的治疗方法和临床材料的供应、成本基础和供应链设计产生重大影响。进口药品活性成分、专用给药装置或成品外用和注射剂的关税增加，可能会促使製造商重新评估筹资策略，并考虑将生产外包或供应商多元化，以缓解利润率压力。同时，经销商和医疗保健系统可能会在临床适用的情况下，将采购重点转向国内替代方案。

将治疗方法、给药途径和最终用户医疗保健环境与开发、部署和交付考虑因素联繫起来的精细细分见解。

细分为评估治疗重点和商业化策略提供了一个结构化的观点。根据治疗类型，该领域将治疗分为非药物疗法和药物疗法，这种区分体现在临床试验设计、支付方合作和治疗路径制定等方面。非药物疗法往往着重于復原和行为终点，而药物疗法则优先考虑生化标靶和耐受性。

美洲、欧洲、中东和非洲以及亚太地区在治疗获取驱动因素、支付方框架和交付系统方面存在细微差异。

区域趋势塑造了临床实践模式、报销模式和供应链选择，对获得和接受外阴疼痛治疗产生重大影响。在美洲，多样化的支付方体系和强大的私人医疗保健网络强调疗效比较、病患报告结果以及在门诊和专科诊疗中可证实的价值。临床医生越来越多地采用多学科诊疗模式，製药公司需要与各相关人员合作，以确保处方集纳入和专科医生的采纳。

一家公司兼顾竞争与合作的策略。

竞争格局由成熟的製药和医疗设备公司、新兴的生技公司以及专注于整合医疗服务的服务供应商组成。成熟公司拥有规模优势、丰富的监管经验和广泛的分销网络，而小规模的创新者则提供差异化的作用机制、以患者为中心的治疗平台和针对性的临床项目。临床服务供应商与药物研发公司之间的合作日益普遍，这有助于收集更丰富的数据，并在真实的临床环境中快速改善治疗通讯协定。

製造商和供应商采取切实有效的措施，协调证据产生、供应弹性和相关人员参与，以实现成功实施。

产业领导者应优先考虑整合证据策略，使临床试验终点与临床医生和支付方重视的真实世界指标一致。投资于检验的患者报告结局 (PRO) 评估工具和纵向观察性研究，将增强药物推广决策和临床指南更新所依据的数据。同时，製药公司在设计产品和医疗设备功能时，必须充分考虑最终用户的人体工学，以支持患者自行用药和看护者辅助的居家照护方案。

我们采用严谨的混合方法研究途径，结合对临床医生的访谈、二手文献的整合以及资料检验，为实际的临床和商业性见解提供了支持。

本研究途径，旨在全面了解临床实践、产品特性和给药模式。主要研究包括对妇科和疼痛管理专科的临床医生、医院和专科诊所的采购经理以及负责治疗药物采购的供应链经理进行结构化访谈。这些访谈深入探讨了影响临床决策的因素、采购限制以及不同给药途径的营运要求。

我们从临床、营运和区域需求等方面进行策略整合，以明确创新和实际应用能够在哪些方面带来医疗保健方面的实质改进。

目前外阴疼痛的治疗格局呈现出临床路径不断扩展、循证医学要求不断提高以及治疗模式多样化的特点，这些因素共同为创新和推广应用创造了多种途径。相关人员若能将产品开发与检验的、以病人为中心的疗效指标结合，投资于稳健的供应链，并在实证医学规划的早期阶段就与临床医师沟通，将更有利于影响治疗标准，并确保相关疗法在医疗机构中的应用。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 外阴疼痛治疗市场（依治疗方法划分）

• 非药物疗法
• 药物治疗

第九章：外阴疼痛治疗市场（依给药途径划分）

• 注射药物
• 口服
• 外用

第十章：外阴疼痛治疗市场：依最终用户划分

• 居家照护
  • 看护者援助
  • 自我管理
• 医院
  • 私立医院
  • 公立医院
• 专科诊所
  • 妇科诊所
  • 疼痛管理诊所

第十一章：外阴疼痛治疗市场：按地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十二章：外阴疼痛治疗市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十三章 外阴疼痛治疗市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十四章：美国外阴疼痛治疗市场

第十五章 中国外阴疼痛治疗市场

第十六章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AbbVie Inc.
• Amneal Pharmaceuticals, Inc.
• Bayer Aktiengesellschaft
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Endo International plc
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• Grunenthal GmbH
• Janssen Pharmaceuticals, Inc.
• Merz Pharma GmbH & Co. KGaA
• Pfizer Inc.
• Sanofi SA
• STADA Arzneimittel AG
• Sun Pharmaceutical Industries Limited
• Taro Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Upsher-Smith Laboratories, LLC
• Viatris Inc.
• Zydus Lifesciences Limited

The Vulvodynia Treatment Market was valued at USD 66.75 billion in 2025 and is projected to grow to USD 73.04 billion in 2026, with a CAGR of 9.93%, reaching USD 129.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 66.75 billion
Estimated Year [2026]	USD 73.04 billion
Forecast Year [2032]	USD 129.51 billion
CAGR (%)	9.93%

Concise contextual overview of vulvodynia clinical complexity, care delivery challenges, and strategic implications for stakeholders seeking targeted solutions

Vulvodynia presents a complex and multifaceted clinical challenge that intersects pain management, gynecology, and chronic care delivery. Patients frequently experience prolonged diagnostic journeys, heterogeneous symptom patterns, and variable responses to treatment modalities. Clinicians are adapting protocols to better stratify patients by symptom phenotype and treatment responsiveness, while researchers continue to explore underlying pathophysiology that spans neurological, inflammatory, and musculoskeletal domains.

Against this backdrop, stakeholders require a consolidated synthesis that translates emerging science into pragmatic clinical and commercial actions. The landscape increasingly rewards interventions that offer clear mechanistic rationale, tolerable safety profiles, and demonstrable improvements in patient-reported outcomes. Meanwhile, payers and providers demand evidence of long-term benefit and feasible pathways for integration into outpatient and home-based care models.

This summary frames the therapeutic environment in operational terms, highlighting critical decision points for product development, clinical adoption, and service design. It emphasizes where clinical need, scientific opportunity, and health system readiness align, and it outlines the strategic priorities that will matter most to manufacturers, clinicians, and health system leaders over the near term.

Transformative clinical, regulatory, and commercial dynamics reshaping treatment paradigms, evidence expectations, and care delivery models for vulvodynia care

Recent years have seen substantive shifts in how vulvodynia is recognized, investigated, and managed across clinical and commercial settings. Diagnostic frameworks have moved toward multimodal assessment that integrates pain mapping, psychosocial evaluation, and pelvic floor function testing, creating pathways for more personalized treatment selection. Concurrently, advances in neuromodulatory techniques, topical formulations with targeted delivery mechanisms, and rehabilitative approaches have broadened therapeutic options that clinicians can tailor to distinct patient phenotypes.

Regulatory emphasis on patient-centered outcomes and real-world evidence is reshaping development strategies, prompting sponsors to prioritize validated patient-reported outcome instruments and longitudinal observational data. Health systems have also increased adoption of integrated care pathways that combine specialist consultation, pelvic floor physiotherapy, and pain psychology, thereby reducing fragmentary care and improving continuity.

Commercially, manufacturers and service providers are aligning with value-based procurement trends by generating comparative effectiveness data and engaging early with formulary decision-makers. Supply chain resilience and nimble manufacturing approaches are gaining prominence, particularly for injectable and topical therapeutics that require cold chain or specialized distribution. Taken together, these shifts are creating an environment where innovation is measured not only by efficacy but also by ease of integration into existing clinical workflows and reimbursement frameworks.

How recent United States tariff shifts are influencing supply chains, procurement strategies, and pricing negotiation dynamics across vulvodynia treatment supply and services

Policy changes in trade and tariff regimes can exert practical effects on the availability, cost base, and supply chain design for therapies and clinical supplies relevant to vulvodynia care. Increased duties on imported active pharmaceutical ingredients, specialized delivery devices, or finished topical and injectable products can prompt manufacturers to reassess sourcing strategies and consider nearshoring or supplier diversification to mitigate margin pressure. In parallel, distributors and health systems may respond by adjusting procurement preferences toward domestically produced alternatives when clinically appropriate.

The cumulative impact of tariff adjustments has also influenced pricing negotiations and contracting approaches. Payers and integrated delivery networks are increasingly focused on total cost of ownership, which includes upstream procurement costs and downstream service utilization. As a result, manufacturers that demonstrate supply chain transparency, predictable lead times, and adaptive pricing mechanisms are better positioned in competitive formulary discussions and institutional tender processes.

Moreover, tariffs can accelerate strategic partnerships between clinical suppliers and local manufacturers to preserve continuity of supply for essential topical formulations, specialized applicators, and ancillary devices. In practice, organizations are prioritizing robust supplier qualification, dual sourcing, and inventory management policies to maintain clinical continuity while absorbing or reallocating incremental cost pressures caused by trade policy shifts.

Granular segmentation-driven insights linking treatment modality, administration route, and end-user care settings to development, adoption, and delivery considerations

Segmentation provides the structural lens through which therapeutic priorities and commercialization strategies should be evaluated. Based on Treatment Type, the field differentiates non-pharmacological approaches from pharmacological interventions, and this distinction informs clinical trial design, payer engagement, and care pathway development. Non-pharmacological modalities often emphasize rehabilitative and behavioral endpoints, whereas pharmacological options prioritize biochemical targets and tolerability profiles.

Based on Administration Route, the analysis spans injectable, oral, and topical formats, each carrying unique clinical, regulatory, and logistical implications. Injectable therapies may require administration in clinical settings and have different cold-chain and safety monitoring considerations; oral agents typically favor ease of use and home administration but face adherence and systemic side-effect considerations; topical formulations prioritize local effect with minimized systemic exposure and demand careful attention to vehicle design and skin tolerability.

Based on End User, the market is studied across Home Care, Hospitals, and Specialty Clinics. The Home Care segment is further considered across caregiver-assisted and self-administered options, which affect device ergonomics, patient education, and remote monitoring needs. The Hospitals segment considers private hospitals and public hospitals, reflecting diverse procurement rules, formulary processes, and care delivery models. The Specialty Clinics segment differentiates gynecology clinics and pain management clinics, each with distinct referral patterns, multidisciplinary collaboration norms, and expectations for evidence of clinical benefit.

Regional treatment adoption drivers, payer frameworks, and delivery-system nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence access

Regional dynamics shape clinical practice patterns, reimbursement models, and supply chain choices in ways that materially affect access to and adoption of vulvodynia therapies. In the Americas, heterogeneous payer systems and a strong private-provider network drive emphasis on comparative effectiveness, patient-reported outcomes, and demonstrable value in outpatient and specialty settings. Clinicians increasingly integrate multidisciplinary care models, and manufacturers must engage diverse stakeholders to secure formulary placement and specialist adoption.

In Europe, Middle East & Africa, variations in regulatory requirements and public procurement frameworks create differentiated pathways to market. National guidelines and regional reimbursement policies often guide clinical adoption, while local manufacturing and distribution partnerships can mitigate cross-border logistical complexity. Stakeholders in this region prioritize scalable models of care that can be adapted to both high-resource tertiary centers and lower-resource community settings.

In Asia-Pacific, rapid expansion of outpatient specialty services, growing investment in women's health research, and rising demand for accessible home-care solutions shape commercialization strategies. Local clinical practice patterns and payer evolution favor interventions that combine clinical efficacy with cost-conscious delivery models. Across all regions, collaboration with local clinical opinion leaders and targeted real-world evidence generation remain central to successful adoption and long-term integration.

Competitive and collaborative company strategies emphasizing evidence generation, delivery innovation, and strategic alliances to accelerate clinical adoption and access

Competitive dynamics reflect a mix of established pharmaceutical and device players, emerging specialty biotechs, and service providers focused on integrated care delivery. Established companies bring scale, regulatory experience, and broad distribution networks, while smaller innovators contribute differentiated mechanisms of action, patient-centric delivery platforms, and targeted clinical programs. Partnerships between clinical service providers and therapeutic developers are becoming more common, enabling richer data collection and faster iteration on real-world treatment protocols.

Manufacturers with robust clinical development capabilities are investing in evidence-generation strategies that emphasize validated patient-reported outcome measures and mechanistic biomarkers to support label claims and payer engagement. Meanwhile, device manufacturers and digital therapeutics companies are differentiating through human-centered design, remote monitoring features, and interoperability with electronic health records to facilitate adoption in outpatient and home settings.

Strategic alliances, licensing transactions, and targeted acquisitions continue to be primary routes for organizations to fill capability gaps, access specialized delivery technologies, or enter new geographic markets. Entities that combine clinical credibility with operational agility and a clear plan for post-launch support will have a competitive advantage in securing institutional adoption and physician endorsement.

Pragmatic, high-impact actions for manufacturers and providers to align evidence generation, supply resilience, and stakeholder engagement for successful adoption

Industry leaders should prioritize integrated evidence strategies that align clinical trial endpoints with real-world measures valued by clinicians and payers. Investing in validated patient-reported outcome instruments and longitudinal observational studies will strengthen dossiers used in formulary discussions and clinical guideline updates. In parallel, manufacturers must design product and device features with end-user ergonomics in mind to support both self-administered and caregiver-assisted home care options.

Operationally, companies should pursue supply chain resilience by diversifying suppliers, qualifying regional manufacturing partners, and establishing clear inventory management policies to address tariff volatility and distribution disruptions. Engaging early with payers and health systems to pilot value-based contracting or outcomes-linked agreements can reduce procurement friction and demonstrate long-term cost-effectiveness. Collaboration with specialty clinics and multidisciplinary care teams will facilitate streamlined referral pathways and support broader adoption across gynecology and pain management practices.

Finally, commercial teams must build clinician-facing education programs and post-launch support services that emphasize practical integration into clinical workflows, reimbursement navigation, and patient education. These investments will accelerate uptake, reduce discontinuation rates, and generate meaningful real-world data that can be leveraged for iterative improvement and payer negotiations.

Rigorous mixed-methods research approach combining clinician interviews, secondary literature synthesis, and data triangulation to underpin actionable clinical and commercial insights

The research approach combined qualitative and quantitative evidence streams to construct a holistic understanding of clinical practice, product attributes, and delivery models. Primary research included structured interviews with clinicians across gynecology and pain management specialties, procurement leads from hospitals and specialty clinics, and supply chain managers responsible for therapeutic sourcing. These discussions provided granular insights into clinical decision drivers, procurement constraints, and operational requirements for different administration routes.

Secondary research synthesized peer-reviewed literature, regulatory documentation, clinical guidelines, and product labeling to validate mechanistic rationale and safety profiles. Data triangulation reconciled findings across sources to ensure consistency and highlight areas of divergence that warrant further investigation. The methodology also incorporated analysis of clinical trial registries and observational study reports to contextualize evolving evidence streams.

Limitations include variability in reporting standards across observational studies and heterogeneity in clinical practice patterns across regions. To mitigate these constraints, the research applied conservative interpretation of heterogeneous datasets and emphasized cross-validated trends supported by multiple independent sources. Ethical considerations guided stakeholder engagement, ensuring confidentiality and adherence to relevant research conduct standards throughout primary data collection.

Strategic synthesis of clinical, operational, and regional imperatives that distills where innovation and pragmatic execution will drive meaningful improvements in care

The current therapeutic landscape for vulvodynia is characterized by expanding clinical pathways, evolving evidence expectations, and diverse delivery models that together create multiple avenues for innovation and adoption. Stakeholders who align product development with validated patient-centered outcomes, invest in supply chain robustness, and engage clinicians early in evidence planning will be best positioned to influence care standards and secure institutional adoption.

Operational agility, strategic partnerships, and a focus on practical integration into outpatient and home-care workflows will determine success in commercializing new therapies and delivery systems. Moreover, regional variations in regulatory and reimbursement environments necessitate tailored market-entry approaches that respect local procurement norms and clinical practice patterns. Evidence generation that emphasizes real-world effectiveness and long-term patient benefit will resonate strongly with payers and providers alike.

In summary, the opportunity for meaningful clinical impact is greatest where scientific innovation meets pragmatic delivery solutions. Organizations that execute with clarity on evidence, supply chain, and stakeholder engagement can both improve patient outcomes and establish durable clinical and commercial positions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vulvodynia Treatment Market, by Treatment Type

• 8.1. Non-Pharmacological
• 8.2. Pharmacological

9. Vulvodynia Treatment Market, by Administration Route

• 9.1. Injectable
• 9.2. Oral
• 9.3. Topical

10. Vulvodynia Treatment Market, by End User

• 10.1. Home Care
  • 10.1.1. Caregiver Assisted
  • 10.1.2. Self Administered
• 10.2. Hospitals
  • 10.2.1. Private Hospitals
  • 10.2.2. Public Hospitals
• 10.3. Specialty Clinics
  • 10.3.1. Gynecology Clinics
  • 10.3.2. Pain Management Clinics

11. Vulvodynia Treatment Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Vulvodynia Treatment Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Vulvodynia Treatment Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. United States Vulvodynia Treatment Market

15. China Vulvodynia Treatment Market

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025
• 16.5. AbbVie Inc.
• 16.6. Amneal Pharmaceuticals, Inc.
• 16.7. Bayer Aktiengesellschaft
• 16.8. Dr. Reddy's Laboratories Ltd.
• 16.9. Eli Lilly and Company
• 16.10. Endo International plc
• 16.11. GlaxoSmithKline plc
• 16.12. Glenmark Pharmaceuticals Limited
• 16.13. Grunenthal GmbH
• 16.14. Janssen Pharmaceuticals, Inc.
• 16.15. Merz Pharma GmbH & Co. KGaA
• 16.16. Pfizer Inc.
• 16.17. Sanofi S.A.
• 16.18. STADA Arzneimittel AG
• 16.19. Sun Pharmaceutical Industries Limited
• 16.20. Taro Pharmaceutical Industries Ltd.
• 16.21. Teva Pharmaceutical Industries Ltd.
• 16.22. Upsher-Smith Laboratories, LLC
• 16.23. Viatris Inc.
• 16.24. Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 11. CHINA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY CAREGIVER ASSISTED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY CAREGIVER ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY CAREGIVER ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SELF ADMINISTERED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SELF ADMINISTERED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GYNECOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GYNECOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GYNECOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 56. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 57. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 62. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 63. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 64. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 67. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 68. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 69. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 70. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 71. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 86. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 88. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 89. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 90. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 91. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 92. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 93. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 95. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 96. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 97. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 98. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 99. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 100. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 101. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 102. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 103. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 104. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 105. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 106. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 110. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 112. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 115. GCC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 116. GCC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 117. GCC VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 118. GCC VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 119. GCC VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 120. GCC VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 121. GCC VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 122. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 124. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 126. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 128. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 129. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 131. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 132. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 133. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 134. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 135. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 136. G7 VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 137. G7 VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 138. G7 VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 139. G7 VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 140. G7 VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 141. G7 VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 142. G7 VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 143. NATO VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 144. NATO VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 145. NATO VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 146. NATO VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 147. NATO VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 148. NATO VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 149. NATO VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 151. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 152. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 153. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 154. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 155. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 156. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 157. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
• TABLE 158. CHINA VULVODYNIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 159. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 160. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
• TABLE 161. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 162. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 163. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
• TABLE 164. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)